The CONDOR consortium is one of the 17 national awardees in the fifth call for projects in Hospital-University Research in Health (RHU5). It involves three expert centers in the management of sarcomas (Institut Bergonié, Institut Gustave Roussy, theCentre Léon Bérard) and Inserm via the Pôle de Recherche Clinique and the Centre de Recherche des Cordeliers, as well as three French companies, each recognized for their expertise in their respective fields: Domain Therapeutics, Explicyte, and Owkin,
Its objective is to implement a multi-modal project combining precision medicine and immunotherapies for the management of patients with Soft Tissue Sarcomas (STS).
“This project represents a unique opportunity to better understand the impact of the immune system in the pathophysiology of sarcomas, to be able to develop innovative and effective treatment strategies,” explains Pr. Wolf-Hervé Fridman, who leads the team involved in the project at the Centre de Recherche des Cordeliers.
STS are a group of rare and heterogeneous tumors – representing 1% and 15% of adult and childhood cancers, respectively. Despite well-conducted locoregional treatment, up to 40% of patients develop a metastatic relapse.
CONDOR is a unique approach aiming to deliver a therapeutic arsenal based on better knowledge of the STS tumor microenvironment, predictive tools and biomarkers to stratify patients, as well as new immunotherapeutic approaches. The ultimate goal is to double the life expectancy of patients with metastatic STS.